CCF642,98.0%
产品编号:Bellancom-100430| CAS NO:346640-08-2| 分子式:C15H10N2O4S3| 分子量:378.45
本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用,
CCF642
产品介绍 | CCF642 是一种有效的蛋白质二硫键异构酶 (PDI) 抑制剂,IC50 为 2.9 μM。CCF642 在多发性骨髓瘤细胞中引起急性内质网 (ER) 应激,并伴随凋亡诱导的钙释放。CCF642 具有广泛的抗多发性骨髓瘤活性。 | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
生物活性 | CCF642 is a potent protein disulfide isomerases (PDI) inhibitor with an IC50 of 2.9 μM. CCF642 causes acute endoplasmic reticulum (ER) stress in multiple myeloma cells accompanied by apoptosis-inducing calcium release. CCF642 has broad anti-multiple myeloma activity. | ||||||||||||||||
体外研究 |
CCF642 (3 μM; 0.5-6 hours) increases PERK dimerization by phosphorylation and IRE1-α oligomerization within 30 minutes in KMS-12-PE confirming accumulation of misfolded ER proteins. 西域 has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot Analysis
|
||||||||||||||||
体内研究 (In Vivo) |
CCF642 (10 mg/kg; i.p.; three times a week; for 24 days) significantly prolongs life of 5TGM1-luc-bearing mice and suppresses 5TGM1-luc growth as determined by life imaging. 西域 has not independently confirmed the accuracy of these methods. They are for reference only.
| ||||||||||||||||
体内研究 |
CCF642 (10 mg/kg; i.p.; three times a week; for 24 days) significantly prolongs life of 5TGM1-luc-bearing mice and suppresses 5TGM1-luc growth as determined by life imaging. 西域 has not independently confirmed the accuracy of these methods. They are for reference only.
| ||||||||||||||||
体内研究 |
CCF642 (10 mg/kg; i.p.; three times a week; for 24 days) significantly prolongs life of 5TGM1-luc-bearing mice and suppresses 5TGM1-luc growth as determined by life imaging. 西域 has not independently confirmed the accuracy of these methods. They are for reference only.
| ||||||||||||||||
性状 | Solid | ||||||||||||||||
溶解性数据 |
In Vitro:
DMSO : ≥ 30 mg/mL (79.27 mM) * "≥" means soluble, but saturation unknown. 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:
——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
| ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
参考文献 |